{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:46:51Z","timestamp":1783986411948,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ejca.2018.09.034","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T22:12:46Z","timestamp":1541196766000},"page":"61-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study"],"prefix":"10.1016","volume":"105","author":[{"given":"Milvia","family":"Zambetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4231-2291","authenticated-orcid":false,"given":"Filippo","family":"Montemurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Morandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba A.","family":"Brandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Bisagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Cagossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Bengala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6320-405X","authenticated-orcid":false,"given":"Stefania","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Iannacone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Stell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.ejca.2018.09.034_bib1","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.034_bib2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3332\/ecancer.2017.732","article-title":"Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer","volume":"11","author":"Morigi","year":"2017","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.ejca.2018.09.034_bib3","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2016.67.0182","volume":"34","author":"Denduluri","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.034_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/14737140.2017.1264876","article-title":"Adjuvant trastuzumab: a 10-year overview of its benefit","volume":"17","author":"Lambertini","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ejca.2018.09.034_bib5","series-title":"Herceptin - summary of product characteristics","year":"2017"},{"key":"10.1016\/j.ejca.2018.09.034_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/17425247.4.4.427","article-title":"Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration","volume":"4","author":"Frost","year":"2007","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.ejca.2018.09.034_bib7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00280-013-2273-z","article-title":"Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males","volume":"72","author":"Wynne","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2018.09.034_bib8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/annonc\/mdu524","article-title":"Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study","volume":"26","author":"Jackisch","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.034_bib9","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mdu364","article-title":"Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study","volume":"25","author":"Pivot","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.034_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.05.010","article-title":"Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients","volume":"82","author":"Gligorov","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.09.034_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.breast.2017.05.004","article-title":"Switching between intravenous and subcutaneous trastuzumab: safety results from the PrefHer trial","volume":"34","author":"Gligorov","year":"2017","journal-title":"Breast Edinb Scotl"},{"key":"10.1016\/j.ejca.2018.09.034_bib12","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2009.26.0125","article-title":"Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?","volume":"28","author":"Morris","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.034_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006915","article-title":"Cardiotoxicity from human epidermal growth factor receptor-2 (HER2) targeted therapies","volume":"6","author":"Florido","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejca.2018.09.034_bib14","unstructured":"An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in pati... | OncologyPRO n.d. http:\/\/oncologypro.esmo.org\/Meeting-Resources\/ESMO-2016\/An-open-label-multinational-multicentre-phase-IIIB-umbrella-study-of-subcutaneous-trastuzumab-with-or-without-chemotherapy-or-pertuzumab-in-patients-with-HER2-positive-early-or-metastatic-breast-cancer-UmbHER1-Interim-safety-results-from-early-breas (accessed October 6, 2017)."},{"issue":"Suppl 7","key":"10.1016\/j.ejca.2018.09.034_bib15","doi-asserted-by":"crossref","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.034_bib16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.034_bib17","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.034_bib18","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.034_bib19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.breast.2015.01.002","article-title":"Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study","volume":"24","author":"Fallowfield","year":"2015","journal-title":"Breast Edinb Scotl"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918314047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918314047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:22:28Z","timestamp":1760732548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918314047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":19,"alternative-id":["S0959804918314047"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.034","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}